Results 111 to 120 of about 3,417 (205)
High and dry: Environmental conditions drive opportunities for disease transmission in desert bighorn sheep
Journal of Applied Ecology, Volume 63, Issue 7, July 2026.By using probabilistic models to predict contacts as a function of spatially and temporally varying environmental conditions, we show that population‐level conditions at the time of disease introduction can structure opportunities for transmission within each population.Diana K. Meza, Amy B. Pedersen, Sophie F. Hawkes, Sara A. Carpenter, Christina M. Aiello, Clinton W. Epps, Richard Ianniello, Paige R. Prentice, Brianna R. Beechler, Anna E. Jolles, Erin E. Gorsich +10 morewiley +1 more sourcePerceptions of Buprenorphine With Naloxone Treatment and the Fear of Precipitated Withdrawal: A Qualitative Exploration With HIV Prevention Trials Network 094 INTEGRA Participants and Staff
Drug and Alcohol Review, Volume 45, Issue 5, July 2026.ABSTRACT Introduction
Uptake of evidence‐based medication for opioid use disorder (MOUD), including buprenorphine–naloxone, remains low despite the expanding US opioid crisis. This study examined participants' and staff perceptions of adopting and delivering buprenorphine–naloxone on a mobile unit providing integrated MOUD and HIV services for people ...Rose A. Schmidt, Amaya Perez‐Brumer, Peter Davidson, Steve Shoptaw, Nabila El‐Bassel, Philip Andrew, Jayla Harris, Omar Nieto, Sydney Bornstein, Rashaunna Redd, Jessica Yeager, David Goodman‐Meza, Albert L. Hasson, Marc Seigel, Cecile Denis, Renee El‐Krab, Laramie R. Smith, on behalf of the HPTN 094 Team +17 morewiley +1 more sourceNeuropsychiatric Adverse Events Associated With Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Clinical Practice: A Multicenter Study
European Journal of Neurology, Volume 33, Issue 7, July 2026.In 214 patients with advanced Parkinson's disease receiving foslevodopa/foscarbidopa continuous subcutaneous infusion, neuropsychiatric adverse events occurred in 19.2%. Baseline cognitive impairment and hallucinations did not increase risk, whereas preexisting impulse control disorders predicted ICD‐related adverse events.David Campo‐Caballero, Jon Rodriguez‐Antiguedad, Arnau Puig‐Davi, Javier Ruiz‐Martinez, Ana Vinagre‐Aragón, Elisabet Mondragón, Lara Pardina Vilella, Nuria López‐Ariztegui, Nuria Caballol, Guillermo González‐Ortega, Iria Cabo, Rocío García Ramos, Inés Legarda, Marta Blázquez‐Estrada, Pilar Sánchez‐Alonso, Pablo Mir, Juan Carlos Romero Fábrega, Silvia Martí Martinez, María Álvarez Sauco, Diego Santos‐García, DATs‐PD GETM Spanish Registry Group, Nuria López Ariztegui, Maria Isabel Morales Casado, Guillermo Tabar Comellas, Asunción Ávila Rivera, Núria Caballol Pons, Anna Planas‐Ballvé, Alejandro Peral Quirós, Dolors Lozano, Diego Santos García, Jose Manuel Paz González, Carlos Cores Bartolomé, Lucia Belen Samaniego Vinueza, Ángela Solleiro Vidal, Iria Cabo, Alejandro Rivero de Aguilar Pensado, Rocío García Ramos, Ana Fernández Revuelta, Eva López Valdés, Ana Aldaz, Carmen Ribacoba Díaz, Inés Legarda Ramírez, Bàrbara Vives Pastor, María Fuensanta Valero García, Marta Blázquez Estrada, Esther Suárez San Martín, Ciara García Fernández, Pilar Tartiere, Patricia Prendes Fernández, Pilar Sánchez‐Alonso, Sabela Novo Ponte, Elisa Gamo González, Raquel Martín García, Pablo Mir Rivera, Laura Muñoz Delgado, Astrid Daniela Adarmes Gómez, Elena Ojeda Lepe, Silvia Jesús Maestre, Daniel Macías García, Fátima Carrillo García, Ana María Castellano Guerrero, Manuela San Eufrasio Martínez, Cristina Pérez Calvo, María López González, Andrés García Herruzo, Cristina Gómez Rapela, Lorena Garrote Espina, Natalia González Rojas, Juan Carlos Romero Fábrega, Francisco Escamilla Sevilla, Lucía Triguero Cueva, Carlos Javier Madrid Navarro, Silvia Martí Martínez, María Álvarez Sauco, Eric Freire Álvarez, Jessica González Ardura, Belén Castaño García, Antonio Sánchez Rodríguez, Déborah Alonso Modino, Jesús Norelis Lorenzo Brito, Maria Esther Rojas Pérez, Carolina Hernández Javier, Jorge Hernández Vara, Maria Victoria González, Sara Belmonte, Débora María Cerdán Santacruz, Amelia Mendoza Rodríguez, Ana Castrillo Sanz, Lorena Caballero Sánchez, Claudia Gómez López de San Román, Álvaro Sánchez‐Ferro, Pablo Rábano Suárez, Antonio Méndez Guerrero, Daniel Pérez Rangel, Jesús Ramírez, Cristina del Álamo Criado, Javier Ruíz Martínez, Elisabet Mondragón Rezola, Ana Vinagre Aragón, Lara Pardina Vilella, David Campo Caballero, Ana Belén Perona Moratalla, Gustavo Fernández‐Pajarín, Maria Pilar Gil Villar, Agustín Sancho Saldana, Laura Quibus Requena, Ángela Monterde Ortega, Juan Carlos Gómez Esteban, Tamara Fernández Valle, Marta Ruiz López, Beatriz Tijero Merino, Susana Cantarero Duque, Guillermo González‐Ortega, Esther Cubo Delgado, Beatriz Alegre García, Lydia López Manzanares, Inés Muro, Elena Casas Peña, Pablo Lorenzo Barreto, Emma Cañada Lahoz, Sara Lozano Veiga, Lydia Vela, Irene Martínez‐Torres, Carlos Morata‐Martínez, Raquel Baviera‐Muñoz, Marina Campins Romeu, Isabel Sastre Bataller, Elena Navarro Mocholí, Roberto López Blanco, Sonia Escalante Arroyo, Tania Delgado Ballestero +130 morewiley +1 more sourceStrengthening health management information systems for Chagas disease: a multi-level qualitative study in Bolivia and Paraguay. [PDF]
Lancet Reg Health AmSkjefte M, Posada E, Torre L, Ardiles Ruesjas S, Galván IL, Chambi W, Soliz Zarate MR, Lesmo V, Rueda E, Morales M, Maude RJ, Rojas-Cortez M, Alonso-Padilla J. +12 moreeuropepmc +1 more sourceDegradomics for large‐scale mechanistic insights on proteases and proteolysis in human health
The FEBS Journal, Volume 293, Issue 13, Page 3881-3898, July 2026.Proteolysis has an important role in human disease but remains relatively unexplored. Degradomics, the uncovering of proteolysis in tissues, cells, and proteins, uses mass spectrometry‐based terminomics to identify protein termini occurring therein (forward degradomics) and to define the actions of proteases (reverse degradomics).Daniel R. Martin, Sumit Bhutada, Suneel S. Apte +2 morewiley +1 more source